Back to Resources
Market Highlights
- Overall, new clinical trial results, a positive CHMP opinion, and an approval were announced within the European lung cancer market during Q3 2025. One brand also introduced new packaging, a price reduction, and availability through a fund.
- CStone Pharmaceuticals announced that Cejemly’s four-year results from GEMSTONE-302 were published in The Lancet Oncology.
- Physicians were advised about Keytruda’s new packaging and price reductions in France. MSD also discussed the brand’s availability through an Italian fund.
- BeOne Medicines informed healthcare professionals about Tevimbra’s positive CHMP opinion for non-small cell lung cancer and approval for three indications.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com